Monoclonal Antibodies in Migraine Prevention: What the Primary Care Physician Needs to Know
Introduction
Pressing Issues for Primary Care
Burden of Migraine
Migraine: Increasing Disability
Primary Headache Disorders: Frequency Classification
Importance of the Headache Diary
ICHD-3 Criteria: Migraine Without Aura
Migraine and Not TTH or Cluster Headache
Migraine and Not Sinus Headache or Neck Problems
Considerations and Criteria for Offering Preventive Migraine Treatment
Migraine Frequency and Preventive Treatment: EMA Indications and Faculty Considerations
Chronic Migraine and Appropriate Preventive Treatment: CaMEO
Eurolight Study: Measuring the Impact of Headache in Europe
Use of Health Care and Use of Migraine Preventive Treatments in Eurolight
European Headache Federation Recommendations for Headache Health Care Service Organization
European Headache Federation Recommendations for Headache Health Care Service Organization (cont)
Challenges in Primary Care
Recommended Migraine Prevention Treatments
Effect of Preventive Drugs: Proportion of Patients With ≥ 50% Reduction in Headache Frequency
Adherence to Conventional Preventive Therapy
Antibody Binding to CGRP Receptor Complex: Target Specificity
Anti-CGRP mAbs: Characteristics
Anti-CGRP mAbs: Clinical Trial Outcomes
Migraine: Pain and Much More
Faculty Recommendations on the Role of the PCP in Migraine Management
Use of Anti-CGRP mAbs: Insight From Germany
Use of Anti-CGRP mAbs: Insight From Ireland
Anti-CGRP mAbs: Challenges in Implementation
Migraine Resources for PCPs
Concluding Remarks
Abbreviations